Status:
COMPLETED
Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The objectives of this study is to obtain information of Faslodex use in the treatment of breast cancer in the clinical practice in Argentina.
Detailed Description
In Argentina, Faslodex is indicated for treating postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-oestroge...
Eligibility Criteria
Inclusion
- Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-estrogen therapy or disease progression during anti-estrogen treatment, currently receiving Faslodex
- Signature of the informed consent
Exclusion
- Any contraindication to Faslodex administration
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00878930
Start Date
April 1 2009
End Date
December 1 2010
Last Update
January 5 2011
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bahía Blanca, Buenos Aires, Argentina
2
Research Site
Campana, Buenos Aires, Argentina
3
Research Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
4
Research Site
La Plata, Buenos Aires, Argentina